#Zent2U, a B2B branch of Zentiva, announces successful completion of pivotal bioequivalence study on value-added Omeprazole immediate-release capsules.
Our new value-added formulation of Omeprazole, containing an antacid, accelerates the absorption of Omeprazole which may bring more value to the patients.
The registration dossier will be available for review in early 2023. We are looking for strong business partners interested in registration and marketing of this unique product in Europe.
#PartnershipForSuccess #ValueAddedMedicine #PatientExperience #Innovation